We provide flexible solutions
adapted to industrial realism
What we do?
For over twenty years, Aptys pharma® has been actively involved in the galenic formulation and design of medicines. This solid experience has led us to develop our own products for licensing or sale.
A unique and
determined vision
Discover our know-how
Aptys pharma® is a research and development company. We implement technologies to formulate or reformulate molecules. Our pharmaceutical and biotechnology expertise enables us to support our clients in the design and formulation, analytical development, and quality control of medicines.
Pain:
a major challenge
What is our commitment to pain management?
Aptys pharma® has been involved with several partners for more than 15 years in the fight against pain by developing an alternative to opiates.
An ongoing challenge
driven by passion
smart technology
Our ambition has always been to design and develop innovative medicines thanks to our proven know-how. Our galenic formulation patents are the synthesis of academic and industrial experience in the field of peptide-based medicines.
inventive
Aptys pharma® has developed many high-tech products under contract or for its own account, with the aim of selling the product once at an advanced stage of development.
our
structure
Two laboratories
- Formulation design laboratory
- Analytical laboratory
Our
achievements
- Preformulation analysis using SoluDiag® and NanoSolution® technology that are two fast and low raw material usage methods.
- Formulation of immediate and controlled release tablets, microspheres, microcapsules, gels, creams, solutions, and suspensions.
- Analytical development, validation, quality control and stability testing.
Latest news
APTYS will attend to Bio Europe Spring in Barcelona
BIO-Europe Spring, the premier springtime partnering event, brings together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one …
Read more
5th Scientific drug delivery conference
📢 François Boutignon, Aptys pharma CEO is honored to chair the upcoming conference
Read more